Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development
of EGFR tyrosine kinase inhibitors (TKIs) marked the beginning of the targeted therapy era
for non-small-cell lung cancer (NSCLC). Thirty percent of NSCLC patients carry EGFR gene
mutations. For these advanced NSCLC patients, EGFR-TKIs are currently preferred for their
superior activity and survival benefits over platinum-based chemotherapy. However …

Mutations in the epidermal growth factor receptor (EGFR) gene are the most common
targetable genomic drivers of non-small cell lung cancer (NSCLC). 90% of the EGFR
mutations comprise of EGFR exon 19 deletion and exon 21 L858R mutation, while EGFR
exon 20 insertion (EGFR Ex20Ins) is the third most common type of EGFR mutation.
Currently, studies on EGFR Ex20Ins are relatively scarce and limited. The frequency of
EGFR Ex20Ins mutations in NSCLC was 1–10%. Patients harboring EGFR Ex20Ins …